1 Hearing loss after exposure to vincristine and platinum-based

2 chemotherapy among childhood cancer survivors

- 3 Sven Strebel, MSc Pharm.^{1,2,3}; Luzius Mader, PhD¹; Philippa Jörger, MSc HST^{1,3}; Nicolas
- 4 Waespe, MD, PhD^{1,2,4}; Seraina Uhlmann, BSc Pharm.¹; Nicolas von der Weid, MD⁵;
- 5 Marc Ansari, MD^{2,6}; Claudia E. Kuehni, MD, MSc^{1,4}
- 6 ¹ Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- 7 ² CANSEARCH research platform in pediatric oncology and hematology, Department of
- 8 Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland
- 9 ³ Graduate School for Health Sciences, University of Bern, Bern, Switzerland
- ⁴ Division of Pediatric Hematology/Oncology, Department of Pediatrics, Inselspital, Bern
- 11 University Hospital, University of Bern, Bern, Switzerland
- ⁵ Department of Pediatric Oncology and Hematology, University Children's Hospital Basel
- 13 (UKBB), University of Basel, Basel, Switzerland
- ⁶ Department of Women, Child and Adolescent, Division of Pediatric Oncology and
- 15 Hematology, Geneva University Hospital, University of Geneva, Geneva, Switzerland
- 16 \square Corresponding author
- 17 Correspondence to: Claudia E. Kuehni, Prof. MD; Institute of Social and Preventive
- 18 Medicine, University of Bern, Mittelstrasse 43, 3012 Bern, Switzerland; E-mail:
- 19 claudia.kuehni@ispm.unibe.ch; Telephone: +41 31 684 35 07

20 ABSTRACT

21	Background: Vincristine poses a suspected additional risk factor for hearing loss among
22	childhood cancer survivors (CCS) treated with platinum-based chemotherapy, yet evidence is
23	scarce since no study reports vincristine doses. We examined the association of vincristine
24	with hearing loss in a national cohort of CCS.
25	Methods: We included CCS registered in the Swiss Childhood Cancer Registry treated at
26	age \leq 18 years with platinum-based chemotherapy between 1990–2014. All participants in our
27	retrospective cohort study had audiogram and treatment data from medical records. We
28	identified CCS exposed to vincristine and calculated the total cumulative dose. We defined
29	clinically relevant hearing loss as grade ≥ 2 using the International Society of Pediatric
30	Oncology Boston Ototoxicity Scale at latest follow-up.
31	Results: Our study population included 270 CCS (43% female; median age at cancer
31 32	<i>Results:</i> Our study population included 270 CCS (43% female; median age at cancer diagnosis 6.8 years; interquartile range [IQR]: 2.1–11.7 years) with median age at audiogram
32	diagnosis 6.8 years; interquartile range [IQR]: 2.1–11.7 years) with median age at audiogram
32 33	diagnosis 6.8 years; interquartile range [IQR]: 2.1–11.7 years) with median age at audiogram 13.5 years (IQR: 9.3–17.0 years). Vincristine exposure was associated with an increased risk
32 33 34	diagnosis 6.8 years; interquartile range [IQR]: 2.1–11.7 years) with median age at audiogram 13.5 years (IQR: 9.3–17.0 years). Vincristine exposure was associated with an increased risk of hearing loss in the multivariable logistic regression analysis (odds ratio [OR] 4.8; 95%
32 33 34 35	diagnosis 6.8 years; interquartile range [IQR]: 2.1–11.7 years) with median age at audiogram 13.5 years (IQR: 9.3–17.0 years). Vincristine exposure was associated with an increased risk of hearing loss in the multivariable logistic regression analysis (odds ratio [OR] 4.8; 95% confidence interval [CI]: 1.8–12.9). We found no evidence of dose-response relationship (OR
 32 33 34 35 36 	diagnosis 6.8 years; interquartile range [IQR]: 2.1–11.7 years) with median age at audiogram 13.5 years (IQR: 9.3–17.0 years). Vincristine exposure was associated with an increased risk of hearing loss in the multivariable logistic regression analysis (odds ratio [OR] 4.8; 95% confidence interval [CI]: 1.8–12.9). We found no evidence of dose-response relationship (OR 1.0; 95% CI: 0.97–1.04) or effect modification from vincristine from other ototoxic
 32 33 34 35 36 37 	diagnosis 6.8 years; interquartile range [IQR]: 2.1–11.7 years) with median age at audiogram 13.5 years (IQR: 9.3–17.0 years). Vincristine exposure was associated with an increased risk of hearing loss in the multivariable logistic regression analysis (odds ratio [OR] 4.8; 95% confidence interval [CI]: 1.8–12.9). We found no evidence of dose-response relationship (OR 1.0; 95% CI: 0.97–1.04) or effect modification from vincristine from other ototoxic treatments, such as type of platinum agent, cranial radiotherapy, and hematopoietic stem cell

41 mechanism and causality among CCS without exposure to other ototoxic cancer treatments.

2

42 KEYWORDS: vinca alkaloids, vincristine, hearing loss, ototoxicity, platinum compounds,
 43 cranial radiotherapy, childhood cancer survivors

44 1. Introduction

45 Hearing loss is a side effect of platinum-based chemotherapy among children.[1] It is 46 usually irreversible and impairs neurocognitive functioning of childhood cancer survivors 47 (CCS).[2, 3] Several studies identified risk factors for platinum-induced hearing loss such as age at diagnosis, type of platinum agent, total cumulative dose of platinum, concomitant 48 cranial radiotherapy (CRT), and hematopoietic stem cell transplantation (HSCT).[4-7] 49 50 However, such factors insufficiently explain interindividual variation of platinum-induced 51 hearing loss, possibly involving additional factors, such as vincristine. [4, 8, 9] Vincristine is 52 known as neurotoxic and reported to cause central neuropathy with paralysis of the auditory nerve (cranial nerve VIII).[10, 11] In addition, vincristine-induced toxicity possibly affects 53 the medial olivocochlear bundle and—to a lesser extent—the outer hair cells.[12] 54

55 Only two studies examined the role of vincristine in platinum-induced hearing loss, 56 highlighting the need for further evidence. [4, 9] Both included vincristine as a co-variable in 57 their analysis but did not further investigate the effect of the total cumulative dose of 58 vincristine and whether there was effect modification between vincristine and other ototoxic 59 cancer treatments. Therefore, we analyzed data from a nationwide cohort of CCS with treatment and audiogram data from medical records to 1) quantify the effect of vincristine on 60 61 platinum-induced hearing loss; 2) test for interactions between vincristine and other ototoxic cancer treatments; and 3) determine a possible dose-response relationship of vincristine-62 63 induced ototoxicity.

3

64 **2.** Methods

65 2.1 Study population

66	We analyzed data from CCS treated with platinum-based chemotherapy between 1990-
67	2014 in the nine specialized pediatric oncology clinics in Switzerland.[6] We included CCS 1)
68	registered in the national and population-based Swiss Childhood Cancer Registry
69	(SCCR),[13] 2) treated for cancer at age \leq 18 years, 3) with no evidence of hearing loss
70	before start of cancer treatment in their medical records, and 4) available audiogram after
71	completing platinum-based chemotherapy.[6] Further details about identifying eligible CCS
72	and data collection are published elsewhere.[6, 14] The Ethics Committee of the Canton of
73	Bern approved the SCCR and the Swiss Childhood Cancer Survivor Study (KEK-BE:
74	166/2014; 2021-01462).[15]

75 **2.2** Study procedure

We collected clinical information on cancer diagnosis and treatment from medical records 76 and the SCCR in 2015.[6, 14] We extracted clinical variables, including sex (female, male); 77 cancer diagnosis according to the International Classification of Childhood Cancer (3rd 78 79 edition)[16]; age at cancer diagnosis (< 5, 5–9, and 10–18 years); period of cancer diagnosis 80 (1990–1995, 1996–2001, 2002–2007, and 2008–2014); type and total cumulative dose (mg/m²) of platinum agents (cisplatin, carboplatin); CRT (yes, no); and HSCT (yes, no). 81 During initial data collection in 2015, no treatment information about vincristine exposure 82 83 was collected. We went through all medical records and treatment protocols again in 2022 and calculated vincristine exposure and total cumulative vincristine dose (mg/m²) as treated or— 84 85 when unavailable—based on treatment protocol.

86 **2.3 Measurement of hearing loss**

87	We determined hearing loss at latest follow-up after completion of platinum-based
88	chemotherapy. We evaluated audiograms with the classification system of the International
89	Society of Pediatric Oncology (SIOP) Boston Ototoxicity Scale.[17] Based on the approach of
90	previous studies, we defined clinically relevant hearing loss (yes, no) as SIOP-Boston grade \geq
91	2.[4, 6] In cases of asymmetric hearing, we took the most affected ear as the reference for
92	grading. Further details on the evaluation of the audiograms were previously published.[6]

93 2.4 Statistical analysis

94 First, we compared the prevalence of clinically relevant hearing loss overall and stratified by type of platinum-based chemotherapy between CCS with and without vincristine exposure. 95 We fitted univariable logistic regression models including sex, age at audiogram, age at 96 97 cancer diagnosis, period of cancer diagnosis, type of platinum-based chemotherapy, exposure 98 to vincristine, concomitant CRT, and HSCT as exposures and clinically relevant hearing loss (yes, no) as outcome.[6] The multivariable regressions included a priori sex, age at most 99 100 recent audiogram, age at cancer diagnosis, and all other clinical characteristics previously 101 associated with hearing loss at P < 0.05 in the univariable models. To examine effect 102 modification of other ototoxic treatments, we included interaction terms between vincristine 103 exposure and type of platinum-based chemotherapy, CRT, and HSCT.[4, 18, 19] We also 104 included the total cumulative dose of cisplatin, carboplatin, and vincristine as a continuous 105 variable in a sub-analysis, which included only CCS who received vincristine, to determine a 106 possible dose-response relationship. We excluded survivors with missing values for the

5

- 107 cumulative dose of vincristine or platinum-based chemotherapy from the regression analysis.
- 108 We calculated global *P*-values using likelihood-ratio tests (LRT).
- 109 We performed a sensitivity analysis to control for additional ototoxic factors, such as brain
- 110 surgeries or cerebrospinal fluid shunts, associated with central nervous system (CNS) tumors
- 111 diagnosis.[1, 20] We included CNS tumor diagnosis (yes, no) as a co-variable in our
- 112 multivariable regression model.
- 113 We used Stata version 16.1 (StataCorp LP, Austin, TX, USA) for all analyses.

114 **3. Results**

115 **3.1** Characteristics of study population

- 116 We included 270 CCS with a median age at cancer diagnosis of 6.8 years (interquartile
- 117 range [IQR]: 2.1–11.7 years) in our analysis (Table 1). A detailed flow-diagram of the study
- 118 population was published elsewhere.[6] Median time from cancer diagnosis to most recent
- 119 audiogram was 5 years (IQR 2.5–8.1 years). The most common cancer diagnoses were CNS
- 120 tumors (n = 104; 39%). Over half (n = 145; 54%) received vincristine with a median total
- 121 cumulative dose of 23 mg/m² (IQR 10.1–40.9 mg/m²) (Supplement Figure A.1). CCS
- 122 previously treated with vincristine were younger at cancer diagnosis, more likely survivors of
- 123 CNS tumors or neuroblastoma, and received more often carboplatin, CRT, and HSCT than
- 124 CCS without vincristine exposure.

125 **3.2** Role of vincristine in platinum-induced hearing loss

126 Of the included CCS treated with vincristine, 49% (95% CI: 41-57) had hearing loss 127 compared with 22% (95% CI: 15-30) of CCS not treated with vincristine (p < 0.001) (Figure 128 1). Stratified by type of platinum-based chemotherapy, we saw the largest difference in 129 prevalence of hearing loss between CCS with and without vincristine exposure among those 130 treated with only cisplatin (68% vs. 21%).

Exposure to vincristine was associated with a higher risk for hearing loss in the univariable (odds ratio [OR] 3.5, 95% CI: 2.0–6.0) and multivariable (OR 4.8, 95% CI: 1.8–12.9) logistic regression analyses (Table 2). Using interaction terms, we found no evidence for effect modification between exposure to vincristine and type of platinum-based chemotherapy,

135	CRT, and HSCT (all <i>P</i> >0.05) (Table 3). In a sub-analysis including only CCS with vincristine
136	exposure, we found no evidence for a linear effect of total cumulative vincristine dose on the
137	risk of hearing loss (OR 1.0, 95% CI: 0.97–1.04) (Table 2) (Supplement Figure A.1).
138	In our sensitivity analysis, diagnosis with a CNS tumor (yes, no) was not associated with
139	an increased risk for hearing loss in the multivariable regression (OR 0.8, 95% CI: 0.2–2.7)
140	(Supplement Table A.1). The effect size of vincristine (yes, no) did not change compared with
141	the model without adjustment for CNS tumor diagnosis (OR 5.3, 95% CI: 1.7–17.0 vs. OR
142	4.8, 95% CI: 1.8–12.9).

143 **4.** Discussion

In our nationwide cohort study of CCS treated with platinum-based chemotherapy, we found the prevalence of platinum-induced hearing loss higher among CCS with additional vincristine than of CCS without vincristine exposure. Vincristine exposure increased the risk of hearing loss fivefold when adjusting for clinical characteristics. However, we found no evidence of a dose-response relationship of cumulative vincristine dose and the risk for hearing loss, or evidence of effect modification by other ototoxic cancer treatments.

Our study is strengthened from analyzing the ototoxicity of vincristine in a large cohort of CCS in terms of overall exposure and considering the total cumulative vincristine dose and potential interactions with other ototoxic cancer treatments. Further strengths include the well-described cohort with clinical data on hearing function, cancer diagnosis, and platinumbased chemotherapy available. However, we cannot conclude whether vincristine is ototoxic independently or only in combination with platinum agents because all included CCS were treated with platinum-based chemotherapy. Furthermore, we had no data on brain surgery or

157 cerebrospinal fluid shunts among survivors of CNS tumors, which have been associated with 158 an increased risk of hearing loss in other studies. [1, 20, 21] Because 70% of CCS in our 159 cohort who received vincristine were diagnosed with CNS tumors and most patients with 160 CNS tumors were exposed to vincristine (97%), we cannot exclude that part of the association 161 of vincristine with hearing loss as possibly explained by other factors associated with the 162 diagnosis of CNS tumors or other concomitant treatments. However, in our sensitivity 163 analysis, CNS tumor diagnosis was not associated with an increased risk of hearing loss and 164 the effect of vincristine remained unchanged after controlling for CNS tumor diagnosis. We 165 also lack data on use of concomitant ototoxic drugs such as aminoglycoside antibiotics and on 166 prophylactic administration of sodium thiosulfate.[1, 22] However, sodium thiosulfate was only recently been approved in the United States for clinical use; it is not yet approved in 167 168 Switzerland.[23] Another limitation is the retrospective study design and the use of non-169 standardized routine data from different clinics.

170 Ototoxicity of vincristine was reported mainly in case studies of adult patients with cancer and in two recent cohort studies involving CCS.[4, 9, 11, 24-27] Moke and colleagues 171 172 examined hearing loss in a large multi-center cohort of 1,481 children, adolescents, and young 173 adults treated with cisplatin.[4] They also collected data on vincristine exposure and reported 174 that vincristine (yes, no) increased the risk for cisplatin-induced hearing loss by a factor of 175 four (OR 3.6) at latest follow-up,[4] which is consistent with our estimate (OR 4.8). However, 176 a direct comparison must be made with caution because Moke and colleagues also included 177 adults in their analysis and the regression models differed in terms of selected co-variables. In 178 another cohort study of 368 pediatric patients with cancer, Meijer and colleagues 179 demonstrated vincristine exposure (hazard ratio 2.9) was an important determinant for the

180 cumulative incidence of cisplatin-induced hearing loss.[9] Neither of the two cohort studies

181 included data on the cumulative dose of vincristine.[4, 9]

We did not observe an effect from higher cumulative doses of vincristine on the risk of 182 hearing loss, yet we had no data on administration method, timing of administration with 183 184 other drugs (particularly platinum agents), pharmacokinetics, drug-drug interactions with 185 azole antifungals, and genetic factors possibly affecting total exposure and toxicity of 186 vincristine. [28-31] Two prospective studies with small sample sizes (N \leq 23) examined 187 ototoxicity of vincristine and included dose information.[12, 32] Lugassy and colleagues 188 enrolled adult patients with cancer (N=23) in their study and did not observe any deleterious 189 effects from vincristine on hearing among patients with moderate dose exposure (mean total 190 dose of 12 mg).[32] One patient on high-dose vincristine (total dose of 24 mg) developed 191 sensorineural hearing loss during the observation period.[32] Riga and colleagues enrolled 192 pediatric patients diagnosed with leukemia in their study (N=15) who had been treated according to the Berlin-Frankfurt-Muenster-95 (BMF-95) protocol. In their study, exposure to 193 194 low and moderate doses of vincristine ($\leq 1.5 \text{ mg/m}^2$ per dose) did not result in any abnormal 195 changes (≥ 15 dB) in mean hearing thresholds levels measured by pure tone audiometry at 196 latest follow-up.[12] But they found abnormalities in transient evoked otoacoustic emissions 197 (TEOAE) and a decrease in contralateral suppression after three cycles of vincristine 198 administration, indicating a measurable neurotoxic effect of vincristine on outer hair cells and 199 the medial olivocochlear bundle.[12] However, the study's short observation period of 22 days 200 does not allow prediction of the reversibility of observed effects or subsequent detection of 201 hearing loss.[12]

202 **5.** Conclusion

203	Our results support emerging evidence for an increased risk of platinum-induced hearing
204	loss with concomitant vincristine administration.[4, 9] Interindividual variability in hearing
205	loss after platinum-based chemotherapy is large and not yet fully understood.[8], which
206	emphasizes the importance of identifying additional risk factors for hearing loss among CCS,
207	such as the neurotoxic treatment vincristine. However, we suggest including TEOAE
208	measurements in further studies to better understand the mechanism and clinical course of
209	vincristine-induced neurotoxicity in the medial olivocochlear bundle and its influence on
210	platinum-induced hearing loss. In addition, we suggest investigating causality of vincristine
211	and hearing loss among CCS without platinum-based chemotherapy or CRT to determine
212	whether vincristine causes permanent hearing loss even without established ototoxic cancer
213	treatments and whether genetic factors possibly play a role.

214 Clinical trial registration

215 Not applicable.

216 Funding source

- 217 This study was supported by the Swiss Cancer League (HSR-4951-11-2019), the
- 218 CANSEARCH Foundation (<u>https://cansearch.ch/</u>), and the European Union's Seventh
- 219 Framework Program for research, technological development and demonstration under grant
- agreement no. 602030. The EU Commission takes no responsibility for any use made of the
- information set out. Further funding comes from Swiss Cancer Research (KLS/KFS-4825-01-
- 222 2019, KFS-5027-02-2020) and Kinderkrebshilfe Schweiz
- 223 (https://www.kinderkrebshilfe.ch/de).

224 Declaration of competing interest

225 The authors declare that they have no known competing financial interests or personal

relationships that could have appeared to influence the work reported in this paper.

227 Acknowledgments

We thank the study team of the Childhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, and the Swiss Childhood Cancer Survivor Study, the data managers of the Swiss Pediatric Oncology Group, the team of the Swiss Childhood Cancer Registry, and our collaborators of the PanCareLIFE project. We further thank the research group of the CANSEARCH research platform in pediatric oncology and hematology of the University of Geneva for their inputs and support. We thank Kristin Bivens from the

- 234 editorial service of the Institute of Social and Preventive Medicine at the University of Bern
- 235 for her editorial suggestions.

236 References

- [1] Landier W. Ototoxicity and cancer therapy. Cancer. 2016;122:1647-58.
- 238 [2] Bass JK, Liu W, Banerjee P, Brinkman TM, Mulrooney DA, Gajjar A, et al. Association
- 239 of Hearing Impairment With Neurocognition in Survivors of Childhood Cancer. JAMA
- 240 oncology. 2020;6:1363-71.
- [3] Orgel E, O'Neil SH, Kayser K, Smith B, Softley TL, Sherman-Bien S, et al. Effect of
- 242 Sensorineural Hearing Loss on Neurocognitive Functioning in Pediatric Brain Tumor 243 Suprimera Pediatria blood & appear 2016;63:527-34
- 243 Survivors. Pediatric blood & cancer. 2016;63:527-34.
- [4] Moke DJ, Luo C, Millstein J, Knight KR, Rassekh SR, Brooks B, et al. Prevalence and
- risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a
- 246 multi-institutional North American cohort study. The Lancet Child & adolescent health.
- 247 2021;5:274-83.
- 248 [5] Clemens E, de Vries AC, Pluijm SF, Am Zehnhoff-Dinnesen A, Tissing WJ, Loonen JJ, et
- al. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer:
- A DCOG late-effects study. European journal of cancer (Oxford, England : 1990).
- 251 2016;69:77-85.
- [6] Strebel S, Mader L, Sláma T, Waespe N, Weiss A, Parfitt R, et al. Severity of hearing loss
- after platinum chemotherapy in childhood cancer survivors. Pediatric blood & cancer.
 2022;69:e29755.
- 255 [7] Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of
- age and the cumulative dose. European journal of cancer (Oxford, England : 1990).
- 257 2004;40:2445-51.
- [8] Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O. Understanding
 platinum-induced ototoxicity. Trends in pharmacological sciences. 2013;34:458-69.
- 260 [9] Meijer AJM, Li KH, Brooks B, Clemens E, Ross CJ, Rassekh SR, et al. The cumulative
- 261 incidence of cisplatin-induced hearing loss in young children is higher and develops at an
- 262 early stage during therapy compared with older children based on 2052 audiological
 263 assessments. Cancer. 2022;128:169-79.

- 264 [10] Madsen ML, Due H, Ejskjær N, Jensen P, Madsen J, Dybkær K. Aspects of vincristine-
- induced neuropathy in hematologic malignancies: a systematic review. Cancer chemotherapyand pharmacology. 2019;84:471-85.
- [11] Mahajan SL, Ikeda Y, Myers TJ, Baldini MG. Acute acoustic nerve palsy associated with
 vincristine therapy. Cancer. 1981;47:2404-6.
- 269 [12] Riga M, Psarommatis I, Korres S, Varvutsi M, Giotakis I, Apostolopoulos N, et al.
- Neurotoxicity of vincristine on the medial olivocochlear bundle. International journal of
 pediatric otorhinolaryngology. 2007;71:63-9.
- 272 [13] Michel G, von der Weid NX, Zwahlen M, Redmond S, Strippoli MP, Kuehni CE.
- 273 Incidence of childhood cancer in Switzerland: the Swiss Childhood Cancer Registry. Pediatric
- blood & cancer. 2008;50:46-51.
- [14] Weiss A, Kuonen R, Brockmeier H, Grotzer M, Candreia C, Maire R, et al. Audiological
 monitoring in Swiss childhood cancer patients. Pediatric blood & cancer. 2018;65.
- 277 [15] Kuehni CE, Rueegg CS, Michel G, Rebholz CE, Strippoli MP, Niggli FK, et al. Cohort
- 278 profile: the Swiss childhood cancer survivor study. International journal of epidemiology.
- 279 2012;41:1553-64.
- [16] Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of
 Childhood Cancer, third edition. Cancer. 2005;103:1457-67.
- [17] Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW, et al.
- 283 Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition,
- and protection, including a new International Society of Pediatric Oncology Boston
- 285 ototoxicity scale. Journal of clinical oncology : official journal of the American Society of 286 Clinical Oncology 2012:30:2408 17
- 286 Clinical Oncology. 2012;30:2408-17.
- 287 [18] Gertson K, Hayashi SS, Trinkaus K, Wan F, Hayashi RJ. Prevalence of Ototoxicity
- 288 Following Hematopoietic Stem Cell Transplantation in Pediatric Patients. Biology of blood
- and marrow transplantation : journal of the American Society for Blood and Marrow
- 290 Transplantation. 2020;26:107-13.
- [19] Bass JK, Hua CH, Huang J, Onar-Thomas A, Ness KK, Jones S, et al. Hearing Loss in
 Patients Who Received Cranial Radiation Therapy for Childhood Cancer. Journal of clinical
- oncology : official journal of the American Society of Clinical Oncology. 2016;34:1248-55.
- 294 [20] Guillaume DJ, Knight K, Marquez C, Kraemer DF, Bardo DM, Neuwelt EA.
- 295 Cerebrospinal fluid shunting and hearing loss in patients treated for medulloblastoma. Journal
- of neurosurgery Pediatrics. 2012;9:421-7.

- 297 [21] Weiss A, Sommer G, Kasteler R, Scheinemann K, Grotzer M, Kompis M, et al. Long-
- 298 term auditory complications after childhood cancer: A report from the Swiss Childhood
- 299 Cancer Survivor Study. Pediatric blood & cancer. 2017;64:364-73.
- 300 [22] Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, et al. Sodium
 301 Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. The New England journal of
- 302 medicine. 2018;378:2376-85.
- 303 [23] Brock P, Meijer A, Kogner P, Ansari M, Capra M, Geller J, et al. Sodium thiosulfate as
- 304 cisplatin otoprotectant in children: The challenge of when to use it. Pediatric blood & cancer.305 2023:e30248.
- [24] Lugassy G, Shapira A. Sensorineural hearing loss associated with vincristine treatment.
 Blut. 1990;61:320-1.
- 308 [25] Aydogdu I, Ozturan O, Kuku I, Kaya E, Sevinc A, Yildiz R. Bilateral transient hearing
- 309 loss associated with vincristine therapy: case report. Journal of chemotherapy (Florence,
- 310 Italy). 2000;12:530-2.
- 311 [26] Kalcioglu MT, Kuku I, Kaya E, Oncel S, Aydogdu I. Bilateral hearing loss during
- 312 vincristine therapy: a case report. Journal of chemotherapy (Florence, Italy). 2003;15:290-2.
- 313 [27] Yousif H, Richardson SG, Saunders WA. Partially reversible nerve deafness due to
- 314 vincristine. Postgraduate medical journal. 1990;66:688-9.
- 315 [28] van de Velde ME, Kaspers GL, Abbink FCH, Wilhelm AJ, Ket JCF, van den Berg MH.
- 316 Vincristine-induced peripheral neuropathy in children with cancer: A systematic review.
- 317 Critical reviews in oncology/hematology. 2017;114:114-30.
- 318 [29] van de Velde ME, Uittenboogaard A, Yang W, Bonten E, Cheng C, Pei D, et al. Genetic
- 319 Polymorphisms Associated with Vincristine Pharmacokinetics and Vincristine-Induced
- 320 Peripheral Neuropathy in Pediatric Oncology Patients. Cancers. 2022;14.
- 321 [30] van de Velde ME, Kaspers GJL, Abbink FCH, Twisk JWR, van der Sluis IM, van den
- 322 Bos C, et al. Vincristine-Induced Peripheral Neuropathy in Pediatric Oncology: A
- 323 Randomized Controlled Trial Comparing Push Injections with One-Hour Infusions (The
- 324 VINCA Trial). Cancers. 2020;12.
- 325 [31] van de Velde ME, Panetta JC, Wilhelm AJ, van den Berg MH, van der Sluis IM, van den
- 326 Bos C, et al. Population Pharmacokinetics of Vincristine Related to Infusion Duration and
- 327 Peripheral Neuropathy in Pediatric Oncology Patients. Cancers. 2020;12.
- [32] Lugassy G, Shapira A. A prospective cohort study of the effect of vincristine on audition.
 Anti-cancer drugs. 1996;7:525-6.
- 330

TABLE 1 Demographic and clinical characteristics of study population

	Total cohort N=270		No Vincristine n=125		Vincristine n=145		<i>P</i> -value ^{<i>a</i>}
Demographic characteristics	n	(%)	n	(%)	n	(%)	
Sex							0.192
Male	154	(57)	66	(53)	88	(61)	
Female	116	(43)	59	(47)	57	(39)	
Age at most recent audiogram							0.066
< 10 years	81	(30)	32	(26)	49	(34)	
10–15 years	108	(40)	47	(38)	61	(42)	
> 15 years	81	(30)	46	(37)	35	(24)	
Clinical characteristics	n	(%)	n	(%)	n	(%)	
Age at cancer diagnosis							< 0.001
< 5 years	112	(41)	42	(34)	70	(48)	
5–9 years	67	(25)	24	(19)	43	(30)	
10–18 years	91	(34)	59	(47)	32	(22)	
Period of cancer diagnosis	71	(31)	57	(17)	52	(22)	0.454
1990–1995	48	(18)	24	(19)	24	(17)	0.104
1996–2001	48 75	(28)	36	(19)	39	(17) (27)	
2002–2007	82	(30)	32	(25)	50	(34)	
2008–2014	65	(24)	33	(26)	32	(22)	
Diagnosis (ICCC-3)	05	(27)	55	(20)	52	(22)	< 0.001
III CNS and miscellaneous intracranial and							<0.001
intraspinal neoplasms	104	(39)	3	(2)	101	(70)	
IV Neuroblastoma and other peripheral nervous							
cell tumors	39	(14)	13	(10)	26	(18)	
V Retinoblastoma	5	(2)	2	(2)	3	(2)	
VI Renal tumors	6	(2) (2)	3	(2) (2)	3	(2) (2)	
VI Hepatic tumors	15	(6)	14	(2) (11)	1	(2) (1)	
VIII Malignant Bone tumors	62	(23)	62	(11) (50)	0	(1) (0)	
IX Soft tissue and other extraosseous sarcoma	12		1	(1)	11	(8)	
X Germ cell tumors, trophoblastic tumors, and	12	(4)	1	(1)	11	(8)	
neoplasms of gonads	27	(10)	27	(22)	0	(0)	
Treatments ^b							
Platinum agent							< 0.001
Cisplatin	151	(56)	98	(78)	53	(37)	<0.001
	62	(56)	98 17	(14)	45	(37)	
Carboplatin Cisplatin and Carboplatin	57	(23)	17				
	57	(21)	10	(8)	47	(32)	< 0.001
Cumulative cisplatin dose categories	(\mathbf{c})	(22)	17	(14)	15	(21)	<0.001
No cisplatin	62	(23)	17	(14)	45	(31)	
$\leq 300 \text{ mg/m}^2$	51	(19)	11	(9)	40	(28)	
$301-450 \text{ mg/m}^2$	71	(26)	38	(30)	33	(23)	
$> 450 \text{ mg/m}^2$	86	(32)	59	(47)	27	(19)	.0.001
Cumulative carboplatin dose categories			0.0	(=		(2-)	< 0.001
No carboplatin	151	(56)	98	(78)	53	(37)	
< 1500 mg/m ²	29	(11)	3	(2)	26	(18)	
$1500-3000 \text{ mg/m}^2$	53	(20)	14	(11)	39	(27)	
> 3000 mg/m ²	32	(12)	6	(5)	26	(18)	
Missing	5	(2)	4	(3)	1	(1)	
Cranial radiation				(a -)		10	< 0.001
No	172	(64)	115	(92)	57	(39)	
Yes	98	(36)	10	(8)	88	(61)	
HSCT							0.004
No	244	(90)	120	(96)	124	(86)	
Yes	26	(10)	5	(4)	21	(14)	

Abbreviations: CNS, central nervous system; ICCC-3, International Classification of Childhood Cancer-Third Edition; HSCT, hematopoietic stem cell transplantation.

^aP-values calculated from chi-square statistics comparing childhood cancer survivors with and without vincristine exposure.

^bEach subject could have had more than one treatment modality.

	SIOP-Boston grade ≤ 1		SIOP-Boston grade ≥ 2		Univariable		Multivariable ^b		Multivariable ^c	
	n=	172	n=	=98	n=270		n=270		n=139	
	n	(%)	n	(%)	OR ^d (95%-CI)	P-value ^e	OR ^d (95%-CI)	P-value ^e	OR ^d (95%-CI)	P-value
Sex						0.778		0.726		0.791
Female	75	(44)	41	(42)	Reference		Reference		Reference	
Male	97	(56)	57	(58)	1.1(0.7-1.8)		1.1 (0.6–2.2)		1.1 (0.4–2.9)	
Age at audiogram						0.006		< 0.001		0.034
< 10 years	63	(37)	18	(18)	Reference		Reference		Reference	
10–15 years	62	(36)	46	(47)	2.6 (1.4-5.0)		7.8 (2.7–22.7)		7.6 (1.4-40.0)	
> 15 years	47	(27)	34	(35)	2.5 (1.3-5.0)		8.0 (2.3–27.2)		4.5 (0.8–25.5)	
Age at cancer diagnosis						0.001	· · · · ·	< 0.001		0.014
< 5 years	61	(35)	51	(52)	3.0 (1.6-5.5)		9.0 (3.0-27.2)		10.1 (1.8-57.2)	
5–9 years	40	(23)	27	(28)	2.4 (1.2–4.8)		2.4 (0.9-6.1)		1.4 (0.4–5.0)	
10–18 years	71	(41)	20	(20)	Reference		Reference		Reference	
Period of cancer diagnosis			-	(-)		< 0.001	- J	0.011	- J	0.037
1990–1995	18	(10)	30	(31)	7.4 (3.1–17.3)		5.4 (1.8–16.1)		7.9 (1.6–39.3)	
1996-2001	46	(27)	29	(30)	2.8 (1.3-6.1)		1.7 (0.6-4.7)		1.3 (0.3–5.4)	
2002-2007	55	(32)	27	(28)	2.2 (1.0-4.7)		1.4 (0.6–3.7)		2.5 (0.7-8.7)	
2008–2014	53	(31)	12	(12)	Reference		Reference		Reference	
Treatments		()		()						
Platinum-based chemotherapy						< 0.001		< 0.001		
Carboplatin only	54	(31)	8	(8)	Reference		Reference		n.a.	
Cisplatin only	94	(55)	57	(58)	4.1 (1.8–9.2)		15.2 (5.0-45.8)		n.a.	
Both platinum agents	24	(14)	33	(34)	9.3 (3.7–23.1)		8.8 (2.8–27.4)		n.a.	
Cumulative cisplatin dose		()		(0.1)	, (0.0 (2.0 2.0.0)			0.008
Per 100 mg/m ² increase	n.a.	n.a.	n.a.	n.a.	n.a.		n.a.		1.6 (1.1-2.3)	
Cumulative carboplatin dose										0.023
Per 500 mg/m ² increase	n.a.	n.a.	n.a.	n.a.	n.a.		n.a.		0.8 (0.7–1.0)	0.020
Vincristine		11141				< 0.001	11100	0.002	010 (01, 110)	
No	98	(57)	27	(28)	Reference	01001	Reference	0.002	n.a.	
Yes	74	(43)	71	(72)	3.5 (2.0–6.0)		4.8 (1.8–12.9)		n.a.	
<i>Cumulative vincristine dose</i>	<i>,</i> .	(15)		(, 2)	2.2 (2.0 0.0)					0.871
Per 1 mg/m ² increase	n.a.	n.a.	n.a.	n.a.	n.a.		n.a.		1.0 (0.97–1.04)	0.071
Cranial radiation						0.001		0.286		0.790
No	122	(71)	50	(51)	Reference	0.001	Reference	0.200	Reference	0., 90
Yes	50	(29)	48	(49)	2.3 (1.4–3.9)		1.7 (0.6–4.4)		1.2 (0.3–4.7)	
HSCT	20	(2))			2.5 (1.1. 5.5)	< 0.001		0.013		0.006
No	166	(97)	78	(80)	Reference	0.001	Reference	0.015	Reference	0.000
Yes	6	(3)	20	(20)	7.1 (2.7–18.4)		5.2 (1.4–19.4)		12.1 (1.7–83.6)	

TABLE 2 Results from univariable and multivariable^a logistic regression analyses

Abbreviations: CI, confidence interval; HSCT, hematopoietic stem cell transplantation; n.a., not applicable; OR, odds ratio; SIOP, International Society of Pediatric Oncology.

^aFactors associated with hearing loss at P < 0.05 were included in the multivariable analyses. Sex, age at audiogram, and age at cancer diagnosis were included in the multivariable model independent of the strength of the association in the respective univariable model.

^bMain analysis including vincristine (yes, no) and exposure to platinum-based chemotherapy (cisplatin, carboplatin, both platinum agents) as categorical variables (N=270).

^cSub-analysis including only childhood cancer survivors (CCS) exposed to vincristine with total cumulative doses of chemotherapy as continuous variables (N=139). CCS with missing dose information (n=6) were excluded from analysis.

^dOdds ratio from univariable and multivariable logistic regression models: OR < 1 indicates that SIOP-Boston grade ≤ 1 is more likely. OR > 1 indicates that SIOP-Boston grade ≥ 2 is more likely.

^eGlobal *P*-value calculated from likelihood-ratio test.

TABLE 3 Interactions between vincristine and other ototoxic cancer treatments

	Multivariable ^a		
	OR ^b (95%-CI)	P-value	
Model 1			
<i>Test for interaction between platinum-based chemotherapy and vincristine</i>		0.274	
Carboplatin	Reference		
Cisplatin \times vincristine exposure	2.8 (0.2-35.2)		
Both platinum agents \times vincristine exposure	0.5 (0.03–11.0)		
Model 2			
Test for interaction between CRT and vincristine		0.200	
No CRT	Reference		
$CRT \times vincristine exposure$	0.3 (0.04–2.0)		
Model 3			
Test for interaction between HSCT and vincristine		0.354	
No HSCT	Reference		
$HSCT \times vincristine exposure$	4.4 (0.18–105.8)		

Abbreviations: CI, confidence interval; CRT, cranial radiotherapy; HSCT, hematopoietic stem cell transplantation; OR, odds ratio.

^aEach interaction between vincristine and the variables platinum-based chemotherapy, CRT, or HSCT was analyzed in a separate multivariable model (Models 1–3) (N=270). Each model was adjusted for sex, age at audiogram, age at diagnosis, period of diagnosis, other ototoxic cancer treatments (i.e. platinum-based chemotherapy, CRT, or HSCT).

^bOdds ratio from univariable and multivariable logistic regression models: OR < 1 indicates that SIOP-Boston grade ≤ 1 is more likely. OR > 1 indicates that SIOP-Boston grade ≥ 2 is more likely.

^cGlobal *P*-value calculated from likelihood-ratio test.




FIGURE 1 Comparison of prevalence of clinically relevant hearing loss between childhood cancer survivors with and without vincristine exposure (N=270). Prevalence is shown for the overall cohort and stratified by type of platinum-based chemotherapy.